Not Signed In - Penwest Announces That Endo Reports Receiving Final FDA Approval For Oxymorphone ER
Sat, 24 Jun 2006 06:00 AM EST
... PenwestPharmaceuticals Co. (Nasdaq: PPCO) today announced that EndoPharmaceuticals Inc., Penwest's partner in the development andcommercialization of oxymorphone extended release tablets (oxymorphone ER),reported that the U.S. [click link for full article] ...
Related Topics
- Vaccine Testing & Approval
- Methylphenidate ER
- Divalproex
- Metronidazole Extended Release
- Niacin Extended Release
- Tacrolimus ointment
- Glipizide
- Well Baby Reports
- Tuberculosis Surveillance Reports
- Mammography
- Chronic Disease At A Glance Reports
- Chronic Disease Notes And Reports
- Vaccine Safety and Adverse Event Reports
- Sexually Transmitted Disease Surveillance Reports
- Amphetamine and Dextroamphetamine ER
- Carcinogens
- Albuterol Oral Tablets
- Etodolac ER
- Tarceva
- Pimecrolimus Cream 1%
email this page
print this page
bookmark this page
feedback on this page
